Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (311-320 of 509) with videos related to

Pageof 51
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 12, 2023
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trialRenaud Sabatier, Frédérique Rousseau, Florence Joly, et al.
British Journal of Cancer|May 3, 2017
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignanciesRastislav Bahleda, Juneko E Grilley-Olson, Ramaswamy Govindan, et al.
BMC Health Services Research|March 30, 2012
Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regionsLionel Perrier, Alessandra Buja, Giuseppe Mastrangelo, et al.
Bulletin Du Cancer|April 12, 2023
[Treatments for rare ovarian tumors: What's new?]Coriolan Lebreton, Stanislas Quesada, Marta Bini, et al.
Gynecologic Oncology|June 26, 2026
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG networkThomas Montassier, Enora Laas, Judicael Hotton, et al.
Journal of Personalized Medicine|April 23, 2022
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3Christelle de la Fouchardière, Pia Gamradt, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumorsGeorge D Demetri, Paolo G Casali, Jean-Yves Blay, et al.
Gynecologic Oncology|July 30, 2020
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT)Félix Blanc-Durand, Claudia Lefeuvre-Plesse, Isabelle Ray-Coquard, et al.
The New England Journal of Medicine|September 4, 2024
Doxorubicin-Trabectedin with Trabectedin Maintenance in LeiomyosarcomaPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 2, 2023
European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumorsUlrika Joneborg, Alice Bergamini, Emelie Wallin, et al.
Pageof 51

Showing results (311-320 of 509) with videos related to

Sort By:
Pageof 51
European Journal of Cancer (Oxford, England : 1990)|January 12, 2023
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trialRenaud Sabatier, Frédérique Rousseau, Florence Joly, et al.
British Journal of Cancer|May 3, 2017
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignanciesRastislav Bahleda, Juneko E Grilley-Olson, Ramaswamy Govindan, et al.
BMC Health Services Research|March 30, 2012
Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regionsLionel Perrier, Alessandra Buja, Giuseppe Mastrangelo, et al.
Bulletin Du Cancer|April 12, 2023
[Treatments for rare ovarian tumors: What's new?]Coriolan Lebreton, Stanislas Quesada, Marta Bini, et al.
Gynecologic Oncology|June 26, 2026
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG networkThomas Montassier, Enora Laas, Judicael Hotton, et al.
Journal of Personalized Medicine|April 23, 2022
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3Christelle de la Fouchardière, Pia Gamradt, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumorsGeorge D Demetri, Paolo G Casali, Jean-Yves Blay, et al.
Gynecologic Oncology|July 30, 2020
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT)Félix Blanc-Durand, Claudia Lefeuvre-Plesse, Isabelle Ray-Coquard, et al.
The New England Journal of Medicine|September 4, 2024
Doxorubicin-Trabectedin with Trabectedin Maintenance in LeiomyosarcomaPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 2, 2023
European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumorsUlrika Joneborg, Alice Bergamini, Emelie Wallin, et al.
Pageof 51